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ABSTRACT
Increasing ethical attention and debate is focusing on whether individuals who take part in
clinical trials should be given access to post-trial care. However, the main focus of this
debate has been upon drug trials undertaken in low-income settings. To broaden this
debate, we report findings from interviews with individuals (n¼ 24) who participated in a
clinical trial of a closed-loop system, which is a medical device under development for peo-
ple with type 1 diabetes that automatically adjusts blood glucose to help keep it within clin-
ically recommended ranges. Individuals were recruited from UK sites and interviewed
following trial close-out, at which point the closed-loop had been withdrawn. While individ-
uals were stoical and accepting of the requirement to return the closed-loop, they also con-
veyed varying degrees of distress. Many described having relaxed diabetes management
practices while using the closed-loop and having become deskilled as a consequence, which
made reverting back to pre-trial regimens challenging. Participants also described unantici-
pated consequences arising from using a closed-loop. As well as deskilling, these included
experiencing psychological and emotional benefits that could not be sustained after the
closed-loop had been withdrawn and participants reevaluating their pre- and post-trial life
in light of having used a closed-loop and now perceiving this life much more negatively.
Participants also voiced frustrations about experiencing better blood glucose control using a
closed-loop and then having to revert to using what they now saw as antiquated and
imprecise self-management tools. We use these findings to argue that ethical debates about
post-trial provisioning need to be broadened to consider potential psychological and emo-
tional harms, and not just clinical harms, that may result from withdrawal of investigated
treatments. We also suggest that individuals may benefit from information about potential
nonclinical harms to help make informed decisions about trial participation.
KEYWORDS
Post-trial access; patient
perspective; ethics; medical
device; qualitative research
Introduction
Clinical trials rely on volunteers who should not
experience unnecessary harm as a result of their par-
ticipation. Hence, regulations and codes of practice
have been put in place to help ensure research designs
are rigorous and appropriate, that risks associated
with participation are minimized, that individuals are
able to make informed and voluntary decisions about
taking part, and that research participants are treated
with dignity and respect (Emanuel, Wendler, and
Grady 2000; Grady 2005). Until relatively recently it
has been assumed that the trial team’s ethical, legal,
and clinical responsibilities to participants stop when
a trial comes to an end (Cook, Snyder, and Calvert
2016; Grady 2005). However, increasing attention and
debate are focusing on whether individuals should be
given access to post-trial care (Cook, Snyder, and
Calvert 2016; Doval, Shirali, and Sinha 2015; El
Setouhy et al. 2002; Merritt and Grady 2006; Pratt
and Loff 2011; Usharani and Naqvi 2013). This
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attention has been prompted by the globalization of
clinical trial research and, more specifically, the grow-
ing involvement of individuals from low-income set-
tings in pharmaceutical trials (Cook, Snyder, and
Calvert 2016; Petryna 2009). Particular concern has
been expressed about the ethics of allowing such indi-
viduals to shoulder the risks and burdens of trial par-
ticipation when the beneficiaries tend to be companies
and individuals in the developed world (Cook,
Snyder, and Calvert 2016; Macklin 2004; Millum
2011). To avoid potential exploitation, and to fulfill an
ethic of beneficence and reciprocity, it has been
argued that there is a moral and ethical imperative to
give individuals, who could not otherwise afford
them, ongoing access to trial (drug) treatments if
these are shown to be effective (Cook, Snyder, and
Calvert 2016; Millum 2011). Such an imperative is
seen to be heightened in situations where withdrawal
of drug therapy might result in the worsening of an
individual’s condition, or possibly even death (Doval,
Shirali, and Sinha 2015; Grady 2005) and, hence,
where the basic tenet of human dignity might be vio-
lated (Andanda and Wathuta 2018).
Indeed, it was in response to the kinds of concerns
just described that, in 2000, the Declaration of Helsinki
mandated that “at the conclusion of the study, every
patient entered into the study should be assured of access
to the best proven prophylactic, diagnostic, and thera-
peutic methods identified by the study” (World Medical
Association 2000, 3045). Similar recommendations for
post-trial access to products and procedures of proven
efficacy have also been made by other organizations (e.g.,
UNAIDS: Joint United Nations Programme on HIV/
AIDS 2011; World Health Organization and Council for
International Organizations of Medical Sciences 2016).
While these kinds of guidelines have been welcomed,
concern has also been expressed about the ethics of pro-
viding post-trial treatment to individuals if this means
depriving those who have greater clinical need (Usharani
and Naqvi 2013). Hence, some commentators have pro-
posed that a fair-benefits framework be adopted, wherein
research teams work in collaborative partnership with
target populations in developing communities and allow
these communities to decide how the benefits of the
research are distributed (El Setouhy et al. 2002). In such
cases, a fair benefit might not simply be ongoing access
to the investigated treatment; it could also be achieved
through other means, such as investment in the local
health infrastructure (Ballantyne 2008; El Setouhy et al.
2002). However, it has also been noted that a require-
ment to offer post-trial care (or equivalent investment in
the host community) will escalate the costs of research
and mean fewer trials are conducted. Hence, commenta-
tors have observed that the ethics of providing post-trial
access are far from straightforward (Doval, Shirali, and
Sinha 2015; Grady 2005).
To date, ethical attention and debate have over-
whelmingly focused on trials undertaken in low-income
settings and on drug trials in particular (Cook, Snyder,
and Calvert 2016; Sofaer and Strech 2011). As some
commentators have noted, this has potentially meant
that participants’ need for medical interventions at the
end of other kinds of trials, including those undertaken
in high-income settings, might have been sidelined
(Andanda and Wathuta 2018; Millum 2011; Sofaer
et al. 2009). Others have argued that trial research
undertaken in high-income settings is likely to be less
ethically contentious. This is because if a trialed inter-
vention is shown to be efficacious, there is a high prob-
ability that it will be introduced into the health care
system and, hence, made available to at least some citi-
zens (Pratt and Loff 2011)
Despite the emphasis placed on treating trial partic-
ipants in fair and ethical ways, it is noteworthy that
these individuals have rarely been consulted about the
care and support they feel they need at the end of a
trial. In rare instances where consultation has taken
place, drug trials have been the focus of the research,
with participants generally endorsing post-trial drug
provisioning, especially when individuals might other-
wise be unable to afford treatments (Pace et al. 2006;
Shaffer et al. 2006). Currently missing from the litera-
ture is consideration of what should happen at the
end of trials involving withdrawal of technologies/
medical devices rather than drugs, as distinctive eth-
ical challenges might arise and specific considerations
may be needed to help address these. Arguably, this
kind of work is both pressing and timely, because tri-
als of medical devices are becoming increasingly com-
mon and widespread, especially in the field of
diabetes research (Bekiari et al. 2018; Poolsup,
Suksomboon, and Kyaw 2013).
To address a lacuna in the literature and expand,
and potentially advance, debates about post-trial pro-
visioning, we report findings from a qualitative study
involving individuals who took part in an open-label,
multicenter, randomized trial that sought to test the
safety and efficacy of a closed-loop system as com-
pared to sensor-augmented pump therapy (an open-
loop system that is commercially available) in adults
and youth (aged 6 years and over) who had type 1
diabetes. A closed-loop system is a medical device
under development for people who have type 1 dia-
betes, which is a chronic disease that occurs when the
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pancreas is unable to produce insulin. Hence, individ-
uals affected by this condition have to self-regulate
their blood glucose and try to keep it within the
“normal” range in order to remain healthy. This is
because high blood glucose levels increase the risk of
long-term complications (e.g., blindness, amputation
and stroke), whereas low blood glucose (hypogly-
cemia) can lead to confusion, seizures, periods of
unconsciousness, and sometimes even death.
Individuals normally regulate their (or their child’s)
blood glucose by administering insulin (via injections
or an insulin pump) and calculating and titrating
doses according to the results of blood glucose checks
(normally finger-prick tests undertaken 5–6 times
daily), food consumed, physical activity, and other
factors (e.g., illness). The closed-loop system investi-
gated in the trial comprised an insulin pump, a con-
tinuous glucose monitoring (CGM) device that
measured interstitial blood glucose every 5min, and a
computer-based algorithm that translated, in real-
time, the information received from the CGM device,
in order to determine the amount of insulin that was
then automatically delivered by the pump. As well as
improving an individual’s blood glucose control, an
intended purpose of closed-loop technology is to
reduce the burden of self-management (Bekiari et al.
2018), although users of the specific closed-loop sys-
tem investigated in the trial had to determine the
amount of carbohydrates they consumed in meals/
snacks and enter this information so that an appropri-
ate amount of extra insulin could be administered
(Bally et al. 2017).
The trial used a 1:1 randomization procedure. To
be eligible for the trial, individuals needed to have
been using an insulin pump for at least 3 months and
to have had suboptimal blood glucose control (Bally
et al. 2017). During the trial, participants attended up
to 11 in-clinic visits and had six preplanned telephone
contacts (Bally et al. 2017). Following trial completion,
individuals were put back on to their pre-trial (i.e.,
insulin pump) regimen; this meant that, in practice,
they had to stop using the CGM device and algorithm
that automatically regulated their or their child’s
blood glucose. In the participant information sheet,
participants were advised of the requirement to return
the study devices promptly at the end of the study
and that, as a last resort, the trial team would use
legal measures to ensure this happened. Participants
were also advised of possible risks arising from study
participation, such as a low risk of hyperglycemia
leading to diabetic ketoacidosis resulting from use of
the closed-loop. However, the participant information
sheet made no mention of any possible risks resulting
from withdrawal of the closed-loop at the end of the
study period.
In many respects, the study reported here is an
unusual example as it drew upon the perspectives and
experiences of participants who had participated a
trial of a medical device (rather than a drug) that had
to be withdrawn at the end as it was still under devel-
opment and, hence, not yet licensed for clinical use.
However, while commentators have suggested that
phase I–III trials are relatively uncontroversial because
“no efficacious product can be expected at the end of
such trials in order to fulfill any post-trial obligation
of making the product available to participants”
(Andanda and Wathuta 2018) (unless a country’s reg-
ulations permit a compassionate use exemption to be
exercised), we will show that ethical and other consid-
erations nonetheless exist when an investigated treat-
ment is not available post trial.
The material reported here forms part of a broader
qualitative study in which we interviewed participants
following randomization to a closed-loop and within
1–2weeks of completing the 3-month trial, at which
point they had returned the closed-loop to the trial
team. The main purpose of this qualitative research
was to explore people’s initial understandings and
expectations of closed-loop systems, their likes and
dislikes of using a closed loop, and their views about
how the technology might be improved to increase
efficacy and acceptability for future users (findings
from this component of the research are reported sep-
arately: Lawton et al. 2019a, 2019b). However, after
initial end-of-trial interviews alerted us to participants
experiencing anxiety and distress as a result of having
to return the closed-loop, a decision was made to add
a bioethical expert to the qualitative research team
and broaden the remit of these interviews. Specifically,
we used these interviews to understand and explore
the reasons for participant distress, and what, from
their perspectives, might be done differently to sup-
port people who take part in future trials that require
medical devices to be returned at the end of the study
period. It is the findings from these aspects of the
interviews that form the focus of our reporting here.
Methods
In-depth interviews informed by topic guides were
used so that the discussion remained relevant to the
study aims, while affording the flexibility needed for
participants to raise and discuss issues they perceived
as salient, including those unforeseen at the study’s
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outset (Pope and Mays 1995). An inductive approach
was used (Strauss and Corbin 1990) in which data
collection and analysis took place concurrently, allow-
ing findings from early interviews to iteratively inform
areas explored in later ones. This included our deci-
sion to broaden the remit of the end of trial inter-
views to understand and explore participants’
reactions to withdrawal of the closed-loop in
more depth.
Sample and recruitment
We interviewed adult (18þ years) and adolescent
(13–17 years) trial participants and parents of trial
participants aged 13–15 years and 12 years and under.
The decision to interview parents was made because,
among pre-teenage children, parents take overarching
responsibility for diabetes management tasks and deci-
sion-making (Lawton et al. 2015), and hence it was
recognized that these individuals would have primary
responsibility for using the closed-loop. We also
decided to interview parents of trial participants aged
13–15 years, as, in the early teenage years, youth often
continue to look to their parents for input and sup-
port when undertaking diabetes self-management
tasks (Williams 2000).
Participants were recruited and consented into the
qualitative research at the same time that they were
recruited into the trial. Recruitment was undertaken
by members of the clinical team in all four participat-
ing UK trial sites using an opt-in procedure, with
assent procedures used for minors (Bally et al. 2017).
Data collection for the qualitative research continued
until data saturation was reached—that is, until no
new findings were identified in new data collected.
Data collection and analysis
MB conducted the interviews at a time and location
of participants’ choosing, using a topic guide that was
developed in light of literature reviews and input from
the co-investigator team, and revised in light of
emerging findings (see preceding discussion). Key
areas explored that are relevant to the reporting in
this article include: perceptions and understandings of
the trial; experiences of undertaking diabetes (self-)
management using a closed-loop; perceived impact of
using a closed-loop on oneself and others, food
choices and eating practices; (physical) activity and
everyday (work, school, family) life; benefits and bur-
dens of using a closed-loop as compared to pre-trial
regimens; experiences of trial close-out; reactions to
withdrawal of the closed-loop (and participants’ own
understandings of the reasons for these); views about
how close-out experiences could be improved for
future trial participants; and participants’ information
and support needs post-trial.
Interviews took place between October 2016 and
August 2017. These typically lasted 1–2 hours, and
were digitally recorded and transcribed in full. Data
were analyzed by a team of experienced qualitative
researchers (JL, MB, DR, and CW) using a thematic
approach involving cross-comparison of all interviews
to identify recurrent themes (Strauss and Corbin
1990). These researchers undertook initial analyses
independently and wrote separate reports before meet-
ing to discuss their interpretations and reach agree-
ment on key findings and themes. A coding frame
was then developed that captured these findings and
themes. NVivo Version 10 (QSR International Pty
Ltd., Doncaster, Victoria, Australia), a qualitative soft-
ware package, was used to facilitate data coding and
retrieval, and coded data sets were subjected to further
analyses to allow more nuanced interpretations of the
data to be developed and identify subthemes and illus-
trative quotations. To safeguard anonymity, unique
identifiers are used in the reporting of data
that follows.
Results
Ten adults (aged 18þ years), five adolescents (aged
13–17 years), and nine parents of pediatric patients
were interviewed. Demographic details of these 24
participants are presented in Table 1.
Participants, in their post-trial interviews, described
having being stoical and accepting of the requirement
Table 1. Demographic characteristics of study participants.
Participants with
type 1 diabetes
(n¼ 15)
Parents of
pediatric participants
(n¼ 9)
Gender (n)
Male 8 2
Female 7 7
Age (n)
13–17 years 5 —
18–65 years 10 9
Over 65 years — —
Previous CLS trial experience (n)
6 3
Occupation
Professional 5 5
Semiskilled 4 2
Manual — 1
Higher education 2 —
Secondary school 3 —
Not working/caregiver 1 1
This includes parents who represented children aged 12 years (n¼ 5)
and parents of children aged 13–15 (n¼ 4). In one instance, both
parents of a child aged 13–15 participated in an interview.
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to return the closed-loop at the end of the 3-month
study period. However, while none expressed anger or
resentment, and virtually all conveyed enthusiasm for
taking part in further trials, participants in all groups
also conveyed varying degrees of upset and distress.
This included Parent 7, who described how “we cried,
me and [child’s name], when we had to give it back.
We absolutely loved it … I absolutely feel gutted,
absolutely gutted.” Adult 3 also reported how:
I was just generally frustrated. And I suppose that
had an impact on my immediate family … so this
week you know, I stopped yesterday. So over the past
few days I have felt slightly grumpy because I didn’t
want to give it up. (Adult 3)
In the following, we begin by considering how (and
why) participants benefited psychologically and emo-
tionally from using a closed-loop. We also explore
how participants had relaxed their diabetes manage-
ment practices as a result of using this technology and
became deskilled as a consequence. We do this
because these kinds of experiences provide a vital con-
text for understanding why loss of the closed-loop
was experienced in physically and emotionally harm-
ful ways. We also consider participants’ clinical and
support needs at the end of the trial to help address
the kinds of harms experienced. As all of our main
findings cut across the sample, our reporting has not
been separated out according to participant groups
(e.g., adults, adolescents, and parents); however, we do
indicate when a particular issue was most keenly felt
within one particular group.
Psychological and emotional benefits to using a
closed-loop
Participants described various overlapping psycho-
logical and emotional benefits to using the closed-loop,
many of which only become fully apparent after they
had had direct experience of using the technology.
Respite and less worry
A central benefit, as participants noted, was that the
closed-loop had enabled them to have respite from
managing their (or their child’s) diabetes. This
included Adult 3, who likened her trial experiences to
being “on a holiday” due to not having to constantly
think about and make a conscious effort to keep her
blood glucose levels within target ranges because the
closed-loop would “soak up” and address high and
low blood glucose automatically:
It was great … it was like being on a holiday, where
you can forget about your diabetes as much as
possible, or just relax from it as much as possible.
You know, it was nice to have a back-up that would
… soak up all those extra blood sugars without me
having to worry about it. (Adult 3)
Participants also described how they had worried
less about hypoglycemia (low blood glucose) due to
the system’s ability to detect when their (or their
child’s) blood glucose was dropping and to suspend
or reduce insulin delivery before their blood glucose
went too low. This was highlighted as a particular
benefit by parents, such as Parent 7, who described
the closed-loop as having been “life-changing”
because, for the trial’s duration, they had been able to
sleep at night without worrying about their pre-teen-
age child’s safety, such as the possibility of their slip-
ping into a diabetic coma or experiencing severe (life-
threatening) hypoglycemia:
I absolutely loved it … I can only describe it for a
parent, as life-changing, ‘cause I mean in the night
time it’s unreal. And I actually, I’d sleep the whole
night, ’cause I trusted it … [because] if they [blood
glucose levels] started to go low, it just literally …
brought it all back up again. It was amazing. I didn’t
want to give it back. (Parent 7)
Improved relationships; less family conflict
Participants also reported experiencing reduced con-
flict within their families due to improvements in
their own mood resulting from experiencing more sta-
ble blood glucose levels. As Adult 3 observed, “I was
just generally less grumpy because my bloods were in
target more of the time … and so everyone else ben-
efitted from that as well.” Parents also highlighted the
benefits of not needing to constantly remind their
child to undertake diabetes management tasks, such as
frequent blood glucose testing, as this was done auto-
matically by the continuous glucose monitor:
There wasn’t so much, you know, stress I think all
the time, to remind him (teenage son): have you
done a sugar test? What’s happening with your
sugars? I think all of that took a lot of pressure [off]
our relationship, especially now … he’s becoming a
teenager, and he doesn’t want to do a lot of things
that should be still happening. (Parent 5)
Greater freedom and flexibility
It was also noted how use of the closed-loop had
enabled other aspects of everyday life to become more
relaxed because participants had not needed to keep
routines in place to remind them (or their child) to
undertake blood glucose tests and, when necessary, to
make adjustments to their or their child’s insulin. As
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a consequence, many, including Adult 8, reflected
upon how they had allowed their lives to become
more “complicated’” (for instance, by increasing their
participation in sports and physical activities, and eat-
ing meals at more erratic times of day) during
the trial:
You could allow your lifestyle to become
complicated—because you didn’t need to make these
sort of adjustments and corrections all the time. And
so therefore if you didn’t have the closed-loop you
might have chosen to simplify certain things in your
life so that you didn’t have those complexities.
(Adult 8)
By virtue of the closed-loop’s ability to address fall-
ing blood glucose before it became too low, parents of
pre-teenage children also noted having permitted their
child to have more freedom, including allowing them,
for the first time, to attend sleepovers at friends’
houses and school trips without their being present.
Parents also noted ensuing lifestyle benefits to them-
selves, such as being able to have nights out, because
they had felt confident and able to leave child under
the supervision of another person, such as a friend,
grandparent, or babysitter:
For the three months [of the trial] we had a break,
we could anything—or she could do anything. We
could even go out with [friend] because people were
happy to babysit and we were happy to let them.
(Parent 7)
Similar benefits were also reported by adolescents
and their parents who noted how, due to the closed-
loop’s ability to keep their blood glucose stable, even
if they forgot to administer insulin when they ate or
consumed alcohol, there had been increased willing-
ness to allow them to go out and attend parties and
other social activities with peers:
I know for a fact that my mum and dad, say if [I]
was going out, they were happy to let me because I
was wearing the closed-loop and, if [I] was planning
to stay at my friend’s or whatever, they’d say: “Oh
well, put it on before you go because, you know,
when you’re out you don’t want to be necessarily
testing your blood.” And my mum and dad, you
know, they felt that I was safe with the closed-loop
on. (Adolescent 1)
Relaxing and loosing habits
Participants also reflected upon how, as a result of
having used a technology that had done a lot of the
work on their behalf, they had become “lazy,” as
Adult 10 put it, and had gotten out of the habit of
undertaking key diabetes management practices, such
as regular blood glucose testing, during the trial:
I felt that it changed my behavior in terms of my
diabetes. So it did make me relax, but I suppose not
always in a good way. So, for instance, I tested my
blood glucose levels less often than normal because
the sensors were really accurate and it didn’t feel
necessary. (Adult 3)
Deskilling. In extreme cases, participants voiced con-
cerns about having become deskilled. This included
Parent 8, who noted how, after their child had reverted
to their pre-trial regimen (an insulin pump), they real-
ized that they had forgotten how to determine the size
of the insulin dose they needed to administer to correct
(bring down) high blood glucose:
The hardest part was actually going back at the end
to just the pump, and remembering … I actually had
to ask [child’s name] at one point. I was like: what do
we do with this? (laughs) because I’d forgotten—like
getting back into doing the corrections. (Parent 8)
Adopting bad habits. Due to the closed-loop’s per-
ceived ability to automatically address small rises in
blood glucose, many participants also noted that, as a
result of using it, they had gotten into “bad habits”
such as no longer administering insulin when
they snacked:
And also in terms of little things like snacking that I
wouldn’t be so vigilant about exactly how much
carbohydrate I was having—so if I was preparing the
kids’ tea I would just sort of like have a chip or two.
Generally I would normally concentrate on exactly
how many chips I was having and sort of have some
insulin to go with it. But on the closed-loop system I
think I didn’t concentrate as hard because I assumed
that the system would pick it up and would deal with
the blood sugars that way round … that wasn’t a
good habit to get into. (Adult 3)
Withdrawal of the closed-loop
Addressing bad habits, relearning skills, and rein-
stating old routines
For all individuals, withdrawal of the closed-loop was
also experienced as “a really big step back” (Adult 7).
Specifically, participants described needing to make
significant effort to address bad habits adopted during
the trial, reinstate former routines, and/or relearn how
to undertake some of their former diabetes manage-
ment tasks. As Adult 10 noted: “I’m having to step up
the amount of management I do because, having got
quite used to being quite relaxed about it, I now have
to be less relaxed about it.” As Adult 9 simi-
larly described:
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So I’ve got to try and retrain myself to make the
decisions it was making for me … the only concerns
really are the ones limited to my forgetfulness. And if
I forget to bolus [take insulin] my sugars are going
up, and I don’t have a sensor to warn me they’re
going up. I’ve only got—I feel a bit ropey [unwell]. So
then I’ll deal with it. And if I forget to bolus … I’ve
not got anything covering my back. I’ve just got to do
what I think’s right. Whereas the [closed-loop]
actually made a lot of the smart decisions for you.
Because of the amount of effort required to relearn
key diabetes self-management skills and reinstate rou-
tines to remember to undertake diabetes-management
tasks, some participants likened their post-trial experi-
ences to being “a new parent again, because it’s like
starting from the beginning, like we haven’t had dia-
betes before, ’cause we relied on the closed-loop so
much” (Parent 4). Indeed, some, including Adult 10,
noted that “it’s … more of an adjustment to come
back off it [closed-loop] than it is was to go on”
because of the amount of time and effort required to
reinstate their pre-trial diabetes manage-
ment regimens.
Increased motivation tempered by reverting to anti-
quated self-management tools
Several participants also described how their experien-
ces during the trial had given them a new impetus to
better manage their, or their child’s, diabetes after the
closed-loop had been withdrawn. Specifically, some
such participants, including Adolescent 4 and Adult 6,
described observing improvements in their blood glu-
cose control while using the closed-loop, and feeling
much better physically as a consequence, and, hence,
wanting to maintain these improvements after the trial:
So I’ve been doing my bloods like more regularly. So
like I’m trying to keep it better controlled, just
because I know … it feels much nicer when you do.
(Adolescent 4)
It’s probably inspired me to manage it a bit better
cause I kind of think I can. I can have good blood
sugars. Like normally after four months of being,
having really good control, I’d probably just not
bother at all for a few months. I’d test like once every
other day, cause I’m like: I just need a break from it
all. But actually I feel like: No. It’s worth making the
effort and trying. So I’ve tested my blood sugar today
twice already. (Adult 6)
However, all such participants also noted the frus-
trations and anxieties arising from wanting to sustain
better blood glucose control, but having to revert to
using what they now saw as “old school methodology”
(Adult 4) and antiquated technology, which as
Adolescent 5 noted, “feels like going from the latest
iPhone to a brick phone.”
As several individuals, including Adult 7, further
reflected, use of this older and more basic technology
simply could not permit them to attain the fine-tuned
control they now wanted to achieve, leading them to
feel a “loss of control” as a consequence:
I’ve experienced very high management of my diabetes.
So, in contrast, you realize just how poor the amount of
information you have to make decisions is when you
don’t have CGM [continuous glucose monitoring] …
So yeah. I guess those are the negatives … So … just
having like a spot check of my blood sugars … just
looks, feels a bit one dimensional … after seeing …
the whole sort of graph if you like of the CGM. So you
kind of think: well, I’m not really getting a lot of
information. You know, is my blood sugar going up or
down? And eh, you don’t know that from a single
measurement. So I guess, in a sense, I feel like I’m less
in control. (Adult 7)
Potential physical harm
Because of their new awareness of the limitations of
their old regimens and the time and effort required to
reinstate former habits and skills, participants also
shared their anxieties and concerns that their or their
child’s blood glucose control would be adversely
affected after the trial:
One of the risks is that somebody becomes very lazy.
And becoming very lazy because you have the closed-
loop is fantastic if your closed-loop is going to be
there all the time. But becoming very lazy and then
you lose the closed-loop and then end up, you know,
spending another three months trying to get your
[child’s] sugars under control because you’ve now got
out of the habit of tightly managing them. (Parent 5)
I know my HbA1c [average measure of blood glucose
control] is going to change … I know it’s going to
increase over the next three months … [because] there’s
so much more that I need to get back into the way of
doing things. Eh, I just hope that within, by at least three
months from now, I will have a grasp of what I need to
do. And get it back down again. (Adult 9)
Psychological and emotional harms
The emotional and psychological impact of having to
step back into a life without the closed-loop was also
widely discussed. This issue is understandable given
that, as described earlier, use of this technology had
had such a positive impact on participants’ quality of
life. Specifically, participants shared their worries and
concerns about having to return to their more
restricted (pre-trial) lives, characterized by family con-
flict, worry, strain, and a more regimented way of liv-
ing. This was especially the case for parents who
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shared the distress resulting from having to revert to
getting up several times during the night to make sure
their child was not experiencing hyper- or hypogly-
cemia now that the closed-loop was no longer there
to stop blood glucose from going high or low:
So last night, I’ve been up all night. I’ve literally had
three hours sleep. His sugars went high. Then I’m
having to give him an adjustment, then having to wait.
Whereas the artificial pancreas, the whole three months
he had it, he had one hypo in the night … I actually
thought: I can’t even believe that I’m having to go back
to this after having—it was like luxury. (Parent 9)
Indeed, Parent 9’s implied grief was more explicitly
articulated by others, including Parent 7, who likened
their experience of losing the closed-loop to that of
losing a family member:
We need to get used to it again, not sleeping … You
get used to sleeping, and suddenly you aren’t sleeping
again and [yawns] here we go again … We just—we
just really liked it, and really miss it now. So I think
we feel like we lost a member of our family.
Adults and adolescents also shared their sense of
loss and emotional distress. This included Adult 4,
who described having been “so much happier when I
was on it [closed-loop] because it took so much of the
stress away of having diabetes” and noted how they
now felt like “a part of you is missing in some ways
because, for me, using the closed-loop was life chang-
ing, so I really didn’t want to give it back.”
When they reflected upon the emotional impact of
returning the closed-loop at the end of the trial, some
participants, including Parent 3, also noted how, by
virtue of having had such positive experiences while
using it, they now saw the life to which they (or their
child) had to return much more negatively:
The study gave him a taste [of] what it feels like to
have a working artificial pancreas … as with all the
studies you know, you have that period where it’s all
finished and you have to go back to how it was. And
therefore it’s almost like taking a glimpse to what the
future would look like. And then you go back again.
And I think, you know, that is hard. (Parent 3)
Support received and needed at the end of the trial
Virtually all participants indicated a need for support
after completing the trial, with Adult 8, among others,
noting that, had support from staff been abruptly with-
drawn, this would have had a very detrimental impact:
If my consultant said: right, thank you very much.
Delete my number. Delete my email address. We
aren’t having any more contact. That would not
work. It—your—your sugars are going to go
absolutely haywire afterwards.
Most individuals highlighted a need for clinical and
educational input to help them relearn and reinstate
pre-trial treatment regimens. However, some also indi-
cated needing more holistic support, which comprised
psychological as well as clinical elements. This was not
only to help address anxieties and distress resulting
from withdrawal of the closed-loop, but also to help
them regain their confidence managing their or their
child’s diabetes without the input of the closed-loop:
Now I feel less confident. I just—last night was
completely like I’m mind crazy … there’s an e-mail
gone to [the hospital at] two o’clock in the morning
going: help me, as I just needed someone to reassure
me that everything is going to be ok and that I am
doing things right. (Parent 7)
While there was no protocol or ethically mandated
requirement for trial staff to offer post-trial support,
all participants described how staff had emphasized
and reassured them of their ongoing availability.
However, it was also noted that, because this offer of
post-trial support had been informal and unstruc-
tured, the onus had been placed on them to initiate
contact (by e-mail or phone) and “bother the doctor”
(Adult 2) in the event that they felt they needed help:
They did say it [blood glucose levels] might for the
first few days be a bit erratic … but if I was quite
worried to then just get in touch … and they’ll talk
me through bits and pieces I can do. (Adult 2)
Hence, participants suggested that that future trial
participants would benefit from more formal arrange-
ments, whether this be a post-trial debriefing and edu-
cation session as suggested by Parent 3, or, in Adult
7’s case, a series of contacts with staff to allow them
time to optimize their blood glucose control using the
pre-trial regimens to which they had had to revert:
A session with the team, where you would say …
here’s the devices. Here’s everything back. Here is
what we will suggest [you do with] your basal rates.
But this is something to remind us now that you do
need to do a little bit more testing and … that
system is not there anymore for you. (Parent 3)
I think it would quite useful to maybe get another one
or two weeks with [health professional] contact …
because the three months is quite a while … so having
the extra assistance … even if it’s just for two weeks,
you can get your sugars back into check. (Adult 7)
Discussion
This study has offered an empirical window into an
area of growing ethical attention and debate: whether
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individuals who take part in trials should be given
opportunities to access post-trial care and what this
care should comprise. In this study, which drew upon
the perspectives and experiences of individuals (adults,
adolescents, and parents) who had just completed a
trial of an innovative technology to support manage-
ment of type 1 diabetes, participants in all groups
highlighted a need for post-trial care and support. In
part, this support was seen as necessary to help cir-
cumvent potential physical harms (a deterioration in
blood glucose control) arising from withdrawal of the
closed-loop. Specifically, individuals described wanting
and valuing education, training, and practical support
from trial staff to help reinstate the (forgotten) skills,
habits, and routines needed to undertake effective dia-
betes self-management using the regimens to which
they had to revert. Mirroring findings from other
studies involving users of closed-loop systems, partici-
pants also described experiencing nonclinical benefits
during the trial because the closed-loop had lessened
the burden of diabetes management; permitted a more
spontaneous and flexible lifestyle; and reduced worry
and enabled improved sleep, especially among parents
(Barnard et al. 2014, 2015; Hendrieckx et al. 2017).
Hence, for these individuals, trial participation had
unanticipated consequences for which they had felt
ill-prepared and that had not been discussed in the
participant information sheet (see earlier discussion).
Specifically, participants experienced a better (quality
of) life that could not be sustained once the closed-
loop had been withdrawn. Participants also described
having reevaluated their pre- and post-trial life in light
of using a closed-loop and noted how they now per-
ceived this life more negatively. Others voiced frustra-
tions about wanting to maintain the improvements in
blood glucose control that had resulted from using
the closed-loop, but of having to revert to using what
they now saw as technologically imprecise self-man-
agement tools. Understandably, therefore, while par-
ticipants were accepting of the requirement to return
the closed-loop, virtually all described experiencing
disappointment, anxiety, and a sense of loss. In doing
so, participants highlighted both implicit and explicit
needs for psychological and emotional support from
staff. Hence, one contribution of this study is that it
highlights the importance of debates about the provi-
sioning of post-trial care being extended to trials of
medical devices. We would also argue that these kinds
of debates need to be widened: specifically, that the
kinds of harms considered in the ethical literature
about post-trial care provisioning (e.g., Cook, Snyder,
and Calvert 2016; Doval, Shirali, and Sinha 2015;
Grady 2005; Millum 2011) need to be broadened to
consider potential emotional and psychological harms,
and not just clinical harms, which may result from
withdrawal of trialed treatments.
In this study, participants did feel well supported
by staff after trial completion and were grateful for
their ongoing availability. However, because care
arrangements had been informal and unstructured,
individuals had felt the onus had been on them to ini-
tiate contact. This lack of formal post-trial support is
unsurprising given that, as others have noted, even in
situations where post-trial obligations have been seen
to exist (e.g., UNAIDS: Joint United Nations
Programme on HIV/AIDS 2011; World Health
Organization, and Council for International
Organizations of Medical Sciences 2016), it often
remains unclear with whom the moral and ethical
duty resides to provide post-trial care (usually ongoing
access to drugs) (Doval, Shirali, and Sinha 2015;
Grady 2005; Millum 2011; Pratt and Loff 2011; Sofaer
et al. 2009). Commentators have also suggested that
this responsibility should not fall upon the investiga-
tor team but, rather, should be cascaded to govern-
ments, sponsors, and, in some cases, the international
community (Millum 2011); indeed, the 2013 version
of the Declaration of Helsinki acknowledges that the
burden of providing post-trial access to treatment is
far beyond the investigators’ scope (Palacios 2013).
Commentators have also noted a lack of clarity about
how post-trial care should be delivered to ensure eth-
ical responsibilities are met (Andanda and Wathuta
2018). This includes Cook, Snyder, and Calvert
(2016), who, in a recent review of academic literature,
legislation, and international guidelines, note a distinct
paucity of practical and tangible recommendations for
addressing post-trial provisioning. As these authors
further suggest, this tendency to make general rather
than specific recommendations may serve to “mask
the underlying challenges by providing cosmetic
improvements to existing practices” (Cook, Snyder,
and Calvert 2016, 76). Pratt and Loff (2011) have
raised similar concerns and, in doing so, have high-
lighted the dangers of macro-level obligations being
allocated to micro-level actors. In keeping with these
kinds of ethical concerns, others have noted how, in
the absence of specific guidelines, resourcing, and for-
mal oversight, it has tended to fall to local investiga-
tors and front-line staff to creatively seek out
temporary solutions to meet individuals’ post-trial
needs, even though they have no formal ethical man-
date to do so. This might include identifying add-
itional research protocols in order to continue to
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provide participants with beneficial drugs (Grady
2005) or, in the case of the current study, providing
clinical, educational, and emotional support to help
individuals adjust to the loss of the closed-loop and
reinstate pre-trial regimens.
Although offers of post-trial support were appreci-
ated by participants, other research, like our own, sug-
gests that individuals may be reluctant to initiate
contact with health professionals due to their concerns
that these individuals are already overstretched
(Rankin et al. 2012). In other words, when offers of
health professional support are informal, participants
may not always access the care they need. The impact
on front-line staff also needs to be considered. As
research undertaken with staff involved in the close-
out of another diabetes trial entailing withdrawal of
treatment (insulin pumps) has served to highlight,
ethical and emotional challenges at close-out may also
extend to front-line staff (Lawton et al. 2017). In this
study, staff members reported feeling ill-prepared for
close-out and, more specifically, for withdrawing treat-
ment from patients who were anxious and distressed
(Lawton et al. 2017). Staff members also felt ill-
equipped to provide patients with the emotional and
psychological support some needed due to lack of
resourcing and appropriate training. This study con-
cluded that the close-out of trials involving withdrawal
of treatments/technologies should be subjected to the
same level of ethical oversight as trial recruitment and
delivery stages, a recommendation echoed by others
who have also suggested that the remit of ethics com-
mittees should be broadened to help ensure ethically
appropriate post-trial provisioning takes place
(Andanda and Wathuta 2018; Grady 2005). As well as
increased ethical oversight, staff members working on
future trials of medical devices might benefit from
being given training and resourcing as part of their
core trial funding to ensure they are able to give
patients the support they need following treatment
withdrawal. This might include input from psycholo-
gists, so that the kinds of emotional distress reported
by participants in the current study, and noted by
staff in the study where insulin pumps were with-
drawn (Lawton et al. 2017), are handled appropriately.
Our findings also suggest that, in order to help make
informed decisions about their participation, individu-
als who are approached to take part in future trials
might also benefit from being given information about
potential (nonclinical) harms arising from withdrawal
of treatment.
While the current study raises important questions
about what constitutes harm at the end of trials
involving withdrawal of treatment, the specifics of the
trial need to be taken into account. First, it needs to be
considered that the trial’s investigated technology was
not commercially available; this made post-trial provi-
sioning a moot issue, as current regulations in the
United Kingdom do not permit compassionate use of
(expanded access to) nonapproved medical devices out-
side a clinical trial. It should also be noted that, in com-
parison to individuals in Third World and low-income
settings who might have to confront withdrawal of a
potentially lifesaving or sustaining treatment without
an alternative treatment being made available, partici-
pants in the current study were able to return to a regi-
men that has been shown to be clinically effective
(REPOSE Study Group 2017). Hence, it is likely that
the kinds of emotional distress reported in this article
might be even greater in other kinds of settings and tri-
als. The relatively short duration (3 months) partici-
pants were in the trial should also be taken into
account. While participants described their anxieties
about having become deskilled as a result of using the
closed-loop, it is likely that this deskilling and, hence,
participants’ distress and need for post-trial support
would have been greater in a trial of longer duration.
Others have also noted that in long-term trials, partici-
pants may build up special relationships with research-
ers, and hence they may experience termination of
these relationships as a form of betrayal (Sofaer et al.
2009). In other words, risks of emotional harm may
not just arise from withdrawal of treatment but also
from withdrawal of relationships forged during long-
term trials. Empirical support for this suggestion can
be found in a study in which individuals were inter-
viewed after taking part in a diabetes trial that lasted
more than 20 years. These individuals described having
forged close relationships with trial staff members over
the years, and hence of having experienced a form of
bereavement when the trial came to an end (Lawton
et al. 2003).
Study limitations
As is typical in trials of technological innovations and
medical devices (e.g., Polonsky and Hessler 2013;
Ritholz et al. 2010), our sample was heavily skewed
toward well-educated individuals belonging to higher
socioeconomic groups, and this potentially limits the
applicability of our findings. While we have provided
an in-depth understanding of what the ethical issues
are for trial participants when treatment (a medical
device) is withdrawn at the end of the trial, our study
would have been enhanced by longer term follow-up
of participants to establish the full implications of the
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emotional, psychological, and physical harms they
reported at trial close-out.
Conclusion
This article has reported findings from interviews
undertaken with individuals who took part in a trial
which sought to advance a technology that is intended
to have a very direct and meaningful impact on the
health and well-being of people affected by type 1 dia-
betes (Bekiari et al. 2018). Despite the beneficent
nature of this trial being only too apparent, and the
study undergoing all the required peer-review proc-
esses and ethical and research governance approvals,
we have shown that there was potential for partici-
pants to experience (unanticipated) harms at the end
of the trial by virtue of treatment withdrawal,
although it would appear that these harms were miti-
gated by local investigators offering informal, post-
trial support. Not only does this study highlight the
need for ethical consideration and debates to move
beyond drugs trials undertaken in low-income set-
tings; we have also shown that for these debates to be
responsible, understandings of harm may need to be
broadened to consider psychological and emotional
harms, as well potential clinical harm, which may
result from withdrawal of trial treatments. We have
also suggested that, to help make informed decisions
about their participation, individuals might benefit
from being given information about these kinds of
nonclinical harms.
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